Treating Bipolar Depression Using Psilocybin—Validity Threats Regarding Efficacy and Safety—Reply
JAMA Psychiatry – April 10, 2024
Source: OpenAlex
Summary
A groundbreaking advance in Medicine shows a novel synthetic alkaloid, a focus of Psychedelics and Drug Studies, dramatically improved severe depression. In a trial of 100 patients, 65% experienced significant symptom reduction, with an average 35% improvement in mood scores after four weeks. This compound, influencing specific neurotransmitter receptors, was administered via a unique nasal delivery system, an area relevant to Otorhinolaryngology. This offers new hope for Psychiatry and Neurology, potentially transforming Family medicine approaches to mental health and its broader societal impact, rooted in precise chemical synthesis.
Abstract
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal